Potential Benefits & Side Effects Observations from preclinical and limited clinical literature
Semaglutide is the active ingredient in two FDA-approved prescription medications: Ozempic, approved for improving blood sugar control in adults with type 2 diabetes, and Wegovy, approved for chronic weight management in adults with obesity or overweight who have at least one weight-related medical condition
Medication disclaimers BLACK BOX WARNING: GLP-1s are contraindicated in individuals with a history of medullary thyroid carcinoma, a family history of such, or in patients with multiple endocrine neoplasia syndrome Type 2
Researchers investigating extracellular matrix reorganization may use this formulation to explore how peptide-mediated pathways affect matrix composition, architecture, and organized collagen deposition
It is rarely a single number written in isolation
Patients on such medications require careful blood glucose monitoring and possible dose adjustments, in line with BNF guidance